TXNRD1 and Miyoshi myopathy: Auranofin and PX-12, a thioredoxin-1 inhibitor, have been shown to disrupt thioredoxin-mediated redox signaling and decrease the proliferation and clonogenicity of MM cells by inhibiting TrxR1/2 and Trx2, respectively.